WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 27, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 24,523,750 shares of its common
WALTHAM, Mass. --(BUSINESS WIRE)--May 9, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 29,900,000 shares of its common
Collaboration to Explore Potential of Complementary Mechanisms of Action for Novel Doublet WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 9, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a clinical
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ:IMGN) ("ImmunoGen" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.50% Convertible Senior Notes due 2021.
PDUFA Date is November 28, 2022 WALTHAM, Mass. --(BUSINESS WIRE)--May 23, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and Drug Administration (FDA) has accepted and filed the
Top-Line Data from New Pivotal Single-Arm Trial, SORAYA, Expected in First Half of 2021 Confirmatory MIRASOL Trial for Mirvetuximab on Track to Start by Year-End Conference Call to be Held at 8:00 a.m. ET Today WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 17, 2019-- ImmunoGen Inc.
ImmunoGen to Receive a $15 Million Upfront Payment; Eligible to Receive Up to $337 Million in Potential Option Fees and Milestone Payments Plus Tiered Royalties on a Per Target Basis WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of
ImmunoGen Grants Lilly Exclusive Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Lilly with ImmunoGen's Novel Camptothecin Platform ImmunoGen to Receive a $13 Million Upfront Payment for Initial Targets; Eligible to Receive an Additional $32.5
Amendments Grant Sanofi Exclusive, Fully-Paid Licenses to Selected Development Compounds ImmunoGen to Receive $30 Million License Fee WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer,
Partnership Accelerates Development Path for Mirvetuximab in Greater China and Expands Huadong Medicine’s Oncology Portfolio with Innovative ADC Combines ImmunoGen’s Lead Clinical Program with Huadong’s Regional Oncology Expertise ImmunoGen to Receive $40 Million Upfront Payment and is Eligible to